1. Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
- Author
-
Kaczmarek MZ, Holland RJ, Lavanier SA, Troxler JA, Fesenkova VI, Hanson CA, Cmarik JL, Saavedra JE, Keefer LK, and Ruscetti SK
- Subjects
- Animals, Caspases genetics, Caspases metabolism, Cell Line, Tumor, Forkhead Box Protein O3, Forkhead Transcription Factors agonists, Forkhead Transcription Factors genetics, Forkhead Transcription Factors metabolism, Mice, Mitogen-Activated Protein Kinases antagonists & inhibitors, Mitogen-Activated Protein Kinases genetics, Mitogen-Activated Protein Kinases metabolism, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction, Azo Compounds pharmacology, Cytotoxins pharmacology, Gene Expression Regulation, Leukemic drug effects, Nitric Oxide Donors pharmacology, Piperazines pharmacology, Prodrugs pharmacology
- Abstract
The nitric oxide (NO) prodrug JS-K, a promising anti-cancer agent, consists of a diazeniumdiolate group necessary for the release of NO as well as an arylating ring. In this study, we research the mechanism by which JS-K kills a murine erythroleukemia cell line and determine the roles of NO and arylation in the process. Our studies indicate that JS-K inhibits the PI 3-kinase/Akt and MAP kinase pathways. This correlates with the activation of the tumor suppressor FoxO3a and increased expression of various caspases, leading to apoptosis. The arylating capability of JS-K appears to be sufficient for inducing these biological effects. Overall, these data suggest that JS-K kills tumor cells by arylating and inactivating signaling molecules that block the activation of a tumor suppressor., (Published by Elsevier Ltd.)
- Published
- 2014
- Full Text
- View/download PDF